Boosting the body's own cannabinoids reduced tic-like behaviors in mice across four genetic strains
The FAAH inhibitor URB597 reduced drug-induced head twitches (a tic model) in all four mouse strains tested, suggesting potential for tic disorder treatment without direct THC side effects.
Quick Facts
What This Study Found
Researchers investigated whether URB597, a drug that boosts the body's own cannabinoid levels by blocking the enzyme that breaks them down, could reduce tic-like behaviors in mice. Head twitches were pharmacologically induced using a serotonin receptor agonist (DOI) to model tic disorders.
URB597 significantly reduced tic-like head twitches across all four mouse strains tested (ABH, C57BL/6N, SJL/J, CD-1), demonstrating that the effect was robust across different genetic backgrounds. The drug caused only mild sedation in one strain and was otherwise well tolerated.
The rationale for this approach was that direct THC use has problematic side effects for tic treatment, while indirectly boosting endocannabinoids through enzyme inhibition might provide therapeutic benefit with fewer side effects.
Key Numbers
Four mouse strains tested. URB597 reduced tic-like behavior in all strains. Mild sedation observed in only one strain (C57BL/6N). Over 10% of children experience transient tics; 1% have Tourette syndrome.
How They Did This
Controlled animal study testing URB597 (FAAH inhibitor) against DOI-induced head twitch responses in four mouse strains chosen to represent diverse genetic backgrounds. Behavioral observations quantified head twitches before and after treatment.
Why This Research Matters
Over 10% of school-age children experience transient tic disorders, and Tourette syndrome affects about 1%. Current treatments have significant side effects. Boosting endocannabinoids rather than using THC directly could offer a better-tolerated approach.
The Bigger Picture
The interaction between serotonin and cannabinoid systems in tic disorders is an emerging research area. This study suggests that modulating the endocannabinoid system indirectly (rather than using THC) could be a viable therapeutic strategy, but human trials are needed.
What This Study Doesn't Tell Us
Mouse head twitches induced by a drug are a model of tics but do not replicate the full complexity of human tic disorders or Tourette syndrome. URB597 has not been tested in human tic patients. The four strains may still not capture human genetic diversity.
Questions This Raises
- ?Would FAAH inhibitors reduce tics in humans with Tourette syndrome?
- ?Could this approach work for adults as well as children?
- ?What is the optimal dosing to reduce tics without sedation?
Trust & Context
- Key Stat:
- URB597 reduced tics across all 4 genetic strains tested
- Evidence Grade:
- Controlled animal study across multiple strains. Promising but no human data for tic disorders.
- Study Age:
- Published in 2015. Research on endocannabinoid modulation for tic disorders continues.
- Original Title:
- Interaction between the endocannabinoid and serotonergic system in the exhibition of head twitch response in four mouse strains.
- Published In:
- Neurotoxicity research, 27(3), 275-83 (2015)
- Database ID:
- RTHC-00934
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Can cannabinoids help with tics?
In this mouse study, a drug that boosts the body's own cannabinoid levels reduced tic-like behaviors across four different genetic backgrounds. Previous research suggested THC might help too, but with more side effects.
How is this different from using marijuana for tics?
Instead of introducing THC from outside, this approach uses a drug (URB597) to prevent the body's own cannabinoids from being broken down. This more targeted approach may provide therapeutic benefits with fewer psychoactive side effects.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-00934APA
Ceci, Chiara; Proietti Onori, Martina; Macrì, Simone; Laviola, Giovanni. (2015). Interaction between the endocannabinoid and serotonergic system in the exhibition of head twitch response in four mouse strains.. Neurotoxicity research, 27(3), 275-83. https://doi.org/10.1007/s12640-014-9510-z
MLA
Ceci, Chiara, et al. "Interaction between the endocannabinoid and serotonergic system in the exhibition of head twitch response in four mouse strains.." Neurotoxicity research, 2015. https://doi.org/10.1007/s12640-014-9510-z
RethinkTHC
RethinkTHC Research Database. "Interaction between the endocannabinoid and serotonergic sys..." RTHC-00934. Retrieved from https://rethinkthc.com/research/ceci-2015-interaction-between-the-endocannabinoid
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.